QLC7401

DRUG3 trials

Sponsors

Qilu Pharmaceutical Co., Ltd.

Conditions

Primary Hypercholesterolemia or Mixed Hyperlipidemia

Phase 2

Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol

Not yet recruitingNCT06750341

Qilu Pharmaceutical Co., Ltd.Primary Hypercholesterolemia or Mixed Hyperlipidemia

Start: 2025-02-28End: 2026-09-30Target: 156Updated: 2024-12-27

Phase 3

QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)

Not yet recruitingNCT07441317

Qilu Pharmaceutical Co., Ltd.Primary Hypercholesterolemia or Mixed Hyperlipidemia

Start: 2026-03-01End: 2028-03-01Target: 780Updated: 2026-03-04

QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia

Not yet recruitingNCT07444086

Qilu Pharmaceutical Co., Ltd.Primary Hypercholesterolemia or Mixed Hyperlipidemia

Start: 2026-03-05End: 2028-02-28Target: 510Updated: 2026-03-02